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Abstract 
 
Helicobacter pylori infection induces acute and chronic inflammation and plays a key 
role in gastric mucosal diseases. H. pylori neutrophil-activating protein (HP-NAP), one of its 
virulence factors, induces not only chemotactic but also oxidative burst responses of 
neutrophils. Activated neutrophils use myeloperoxidase (MPO) to generate many cytotoxic 
oxidants, which might result in gastric mucosal injury. In this study, we evaluated whether 
HP-NAP could promote MPO release from human neutrophils. Recombinant HP-NAP 
expressed in Escherichia coli was purified by two sequential gel filtration chromatographies 
and then subjected to syringe filtration for endotoxin removal. The purified recombinant 
HP-NAP assembles into a multimer with a secondary structure of the typical α-helix. In 
addition to stimulating the production of reactive oxygen species, HP-NAP is able to induce 
the secretion of MPO in human neutrophils. The increased MPO release from neutrophils 
induced by HP-NAP may be related to the pathogenesis of H. pylori-associated gastritis. 
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Helicobacter pylori infects over half of the human population [1]. Infection with H. 
pylori is associated with chronic gastritis, peptic ulcer disease and gastric cancer [2]. H. 
pylori infection elicits an inflammatory cell response, and the severity of mucosal injury 
appears to be directly correlated with the extent of neutrophil infiltration [3,4]. The water 
extract, sonicate, and culture supernatant of H. pylori were able to induce neutrophil 
activation and chemotaxis [5-8]. Thus, the presence of bacterial factors of H. pylori to attract 
and activate neutrophils might contribute to H. pylori-induced gastritis. 
 
H. pylori neutrophil-activating protein (HP-NAP), a 150 kDa protein first isolated from 
water extract of H. pylori, was identified to be able to stimulate the production of reactive 
oxygen species (ROS) in neutrophils and promote adhesion of neutrophils to endothelial cells 
[9]. HP-NAP is a spherical dodecamer formed by twelve identical monomers [10,11]. Each 
monomer is a four-helix bundle protein with a molecular weight of ∼17 kDa [10]. The 
presence of a large number of positively charged residues on the surface of HP-NAP might 
account for its unique ability in activating human leukocytes [11]. 
 
HP-NAP induces dose-dependent ROS production and chemotaxis in neutrophils and 
monocytes [12]. HP-NAP also induces the release of IL-8 and CCL4 in neutrophils [13], the 
production of tissue factor, tumor necrosis factor alpha (TNF-α), IL-6, and IL-8 in monocytes 
[14,15], and the release of β-hexosaminidase and IL-6 in mast cells [16]. TNF-α and IFN-γ 
are able to prime human neutrophils to potentiate the effect of HP-NAP on ROS production 
[12]. Such priming effects may be relevant to the in vivo situation, where a synergistic effect 
between HP-NAP and cytokines could amplify the pathogenic effect of ROS. The production 
of ROS and those cytokines may also act as pro-inflammatory signals to induce inflammation 
and degeneration of the stomach mucosa. Thus, HP-NAP might play a role in immune 
pathogenesis of H. pylori infection. 
 
The hallmark of chronic gastritis caused by H. pylori infection is infiltration of 
neutrophils into gastric mucosa [17]. Mucosal biopsy specimens from patients with H. pylori 
infection showed increased amounts of ROS and myeloperoxidase (MPO) [3,7,18,19]. In 
addition, H. pylori density and neutrophils infiltration were correlated with MPO level in 
gastric antral mucosa [19]. MPO possesses potent proinflammatory properties and may 
contribute directly to tissue injury. The secretion of MPO from neutrophils can be induced 
directly by bacterial factors. Indeed, H. pylori sonicate proteins stimulate neutrophil 
degranulation with MPO release in a concentration-dependent manner [7]. H. pylori water 
extract also increases the secretion of MPO from human neutorphils [19]. However, the 
protein component of H. pylori stimulating MPO release from neutrophils has not been 
identified. In this study, we have characterized the recombinant HP-NAP expressed in 
Escherichia coli by examining its physical characteristics and ability to induce ROS 
production in neutrophils. Most importantly, the release of MPO from human neutrophils 
induced by HP-NAP has been investigated. 
 
 
Materials and methods 
 
Reagents. Isopropyl-β-D-thiogalactopyranoside (IPTG) was purchased from MDBio 
(Taipei, Taiwan). Ficoll-Paque PLUS and dextran 500 were purchased from GE Healthcare 
Bio-Sciences (Uppsala, Sweden). Phenylmethylsulfonyl fluoride (PMSF) was purchased 
from Roche (Basel, Switzerland). N-α-p-tosyl-L-lysine chloromethyl ketone hydrochloride 
(TLCK), N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), phorbol 12-myristate 
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13-acetate (PMA), 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol), 3,3′,5,5′-tetramethyl 
benzidine (TMB), myeloperoxidase (MPO) from human leukocytes, bovine serum albumin 
(BSA), and lipopolysaccarides (LPS) from E. coli O111:B4 were purchased from Sigma–
Aldrich (St. Louis, MO). LPS was dissolved in deionized water to a stock concentration of 
1 mg/mL and stored at −20 °C until use. 
 
Production of recombinant HP-NAP.Escherichia coli BL21(DE3) cells harboring 
pET42a-NAP (see Supplemental material) were grown in 5 mL of LB broth containing 
50 μg/mL kanamycin at 37 °C. The overnight culture (1 mL) was inoculated into 100 mL of 
fresh media and cultured at 37 °C until the OD600 reached 0.4. The expression of HP-NAP 
was induced by adding 0.4 mM IPTG and the culture was incubated for 3 h at 37 °C until the 
OD600 reached ∼1.7. Then, cells were harvested by centrifugation and washed once with 
Dulbecco’s phosphate-buffered saline (D-PBS), pH 7.2. The cell pellet was resuspended in 
10 mL of ice-cold D-PBS, pH 7.2, with a protease inhibitor mixture containing PMSF, TLCK, 
and TPCK [20]. After disruption of cells by the high pressure homogenizer (Avestin Inc., 
Ottawa, Canada) at 17,000 psi, soluble proteins were isolated by centrifugation at 30,000g at 
4 °C for 1 h. Five milliliters of supernatant was subjected to gel filtration using a XK 16/100 
column packed with ∼180 mL of Sephacryl S-300 high resolution resin (GE Healthcare 
Bio-Sciences). The column was pre-equilibrated with D-PBS, pH 7.2, at a flow rate of 
1 mL/min by ÄKTA Prime. The eluted fractions containing recombinant HP-NAP were 
further purified through a HiLoad 16/60 Superdex 200 prep grade gel filtration column (GE 
Healthcare Bio-Sciences) equilibrated with D-PBS, pH 7.2, by ÄKTA FPLC at a flow rate of 
1 mL/min. Recombinant HP-NAP was eluted as a single peak. The peak fractions containing 
HP-NAP were pooled and stored at 4 °C no more than 1.5 months before use. The purity of 
HP-NAP was higher than 98% as confirmed by SDS–PAGE stained with PhastGel Blue R. To 
remove endotoxin from purified HP-NAP, pooled fractions were subjected to syringe 
filtration through the Acrodisc unit with positively-charged, hydrophilic Mustang E 
membrane (Pall, East Hills, NY). The amount of endotoxin present in recombinant HP-NAP 
was less than 14 endotoxin unit (EU)/mg protein. 
 
Isolation of human neutrophils. Peripheral venous blood samples from six healthy 
volunteer donors, who signed informed consents, were drawn in vacuum blood collection 
tubes containing heparin. Heparinized blood was mixed with an equal volume of 3% dextran 
in 0.9% saline solution and incubated at room temperature for 20 min to sediment 
erythrocytes. The leukocyte-rich plasma (upper layer) was centrifuged at 250g at 5 °C for 
10 min. Then, the pellet was resuspended with 0.9% saline solution and layered onto 
Ficoll-Paque PLUS. After centrifugation at 400g for 40 min at 20 °C with no brake, the pellet 
was subjected to two 30-s hypotonic treatments to remove contaminated erythrocytes. The 
final cell pellet was resuspended in Hanks’s Balanced Salts Solution (HBSS), kept on ice, and 
used within 5 h. More than 92% of the leukocytes were neutrophils as judged by light 
microscopic examination of at least 600 cells on each Wright’s stained cytocentrifuged slide. 
The cell viability exceeded 91% as gauged by trypan blue exclusion test. 
 
Chemiluminescence assay for ROS production. Isolated human neutrophils adjusted to 
2 × 106 cells/mL in HBSS were dispensed as 50 μL into a white 96-well plate (Packard, 
PerkinElmer, Boston, MA) and incubated at 37 °C. Subsequently, 150 μL of the mixture 
containing luminol and a stimulus in D-PBS was added into each well to a final volume of 
200 μL. Luminol was maintained as a stock solution of 2 mM in dimethyl sulfoxide (DMSO) 
at room temperature and diluted in D-PBS immediately before use. The final concentration of 
luminol in the assay mixture was 10 μM. PMA, a positive stimulus, was maintained as a 
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stock solution of 0.16 mM in DMSO at −20 °C until use. The final concentrations of 
recombinant HP-NAP and PMA were 1 and 0.08 μM, respectively. The emission of 
chemiluminescence was monitored in triplicate over a period of time by Wallac 1420 
Multilabel Counter (PerkinElmer). 
 
Assessment of MPO activity. Neutrophils (1.5 × 105 cells) were incubated with 1 μM 
HP-NAP, 1 μg/mL LPS, or 0.08 μM PMA for 30 min at 37 °C in a final volume of 150 μL. 
The cells were spun down by centrifugation at 1000g at 4 °C for 5 min. Then, 50 μL of each 
supernatant was mixed with 100 μL of TMB liquid substrate. After 30-min incubation at 
room temperature, the reaction was stopped by the addition of 100 μL of 1 M sulfuric acid. 
The absorbance of each reaction was measured at 450 nm using a THERMOmax microplate 
reader (Molecular Devices, Canton, MA). To determine the activity of MPO release from 
neutrophils, the data were applied to the standard curve, which was obtained by plotting the 
absorbance versus the corresponding known concentration of MPO diluted in D-PBS. MPO 
activity was expressed as units of activity per milliliter of supernatant. 
 
 
Results 
 
Purification and characterization of recombinant HP-NAP expressed in E. coli 
 
HP-NAP was expressed in E. coli BL21(DE3) transformed with pET42-NAP plasmid 
under the induction of IPTG. As shown in Fig. 1A, recombinant HP-NAP was expressed as 
soluble proteins and revealed a molecular weight of ∼17 kDa as analyzed by SDS–PAGE. A 
Sephacryl S-300 gel filtration column was used to purify recombinant HP-NAP. On the 
elution profile, the second peak corresponds to HP-NAP as confirmed by SDS–PAGE (Figs. 
S1 and S2). The fraction of this peak was further separated by a Superdex 200 gel filtration 
column, and HP-NAP was mainly eluted as a single peak (Figs. 1B and Fig. S2). The purity 
of HP-NAP was over 98%, and the yield of the protein was ∼4.67 mg from 50 mL E. coli 
culture. 
 
 
 
Fig. 1. Expression and purification of recombinant HP-NAP in E. coli. (A) Expression of HP-NAP in E. coli. E. 
coli BL21(DE3) harboring pET42a-NAP plasmid was induced in the absence (−) or presence (+) of IPTG. Whole cell 
lysate (W) was centrifuged to separate insoluble pellet (I) and soluble fraction (S). The samples were analyzed by 
18% SDS–PAGE. (B) The UV absorbance profile of HP-NAP purified from a Superdex 200 gel filtration column. 
The fraction containing HP-NAP eluted from a Sephacryl S-300 HR column was applied to a Superdex 200 prep 
grade (Superdex 200 pg) column and subsequently eluted with D-PBS, pH 7.2. The eluent was monitored at 280 nm. 
(C) Native PAGE analysis of recombinant HP-NAP. The protein samples including whole cell lysate (W), soluble 
fraction (S), and the peak fractions containing the most abundant HP-NAP eluted from Sephacryl S-300 HR and 
Superdex 200 pg gel filtration columns were analyzed by 10% native PAGE. Molecular weights (M) in kDa are 
indicated on the left of the stained gels (A,C) or at the top of the chromatogram (B). 
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From gel filtration analysis, the molecular weight of recombinant HP-NAP was 
∼150 kDa (Fig. 1B), which is similar to the reported molecular weight of HP-NAP purified 
from H. pylori[9]. From native PAGE analysis, purified HP-NAP was visualized as a single 
band with apparent molecular weight of ∼232 kDa (Fig. 1C). In addition, HP-NAP 
sedimented as a major peak at 9.38 S as analyzed by analytical ultracentrifugation (Fig. 2B), 
indicating the multimeric association of recombinant HP-NAP. The circular dichrosim 
spectrum of recombinant HP-NAP has a line shape that is typical of an α-helix (Fig. 2D), 
which is consistent with the previous reports [10,11]. Thus, recombinant HP-NAP expressed 
in E. coli assembled into a multimer with high helix content. 
 
 
 
 
Fig. 2. Physical characteristics of recombinant HP-NAP expressed in E. coli. (A) Sedimentation 
coefficient of recombinant HP-NAP. The sedimentation analysis of HP-NAP was determined by 
analytical ultracentrifugation. The sedimentation coefficient distribution c(S) is shown as a function of S. 
The c(S) distribution was analyzed by using the software program SEDFIT. (B) Far UV circular 
dichroism spectrum of recombinant HP-NAP. Secondary structure of recombinant HP-NAP in D-PBS, pH 
7.2, were determined by circular dichroism spectroscopy in the far UV spectral region (195–260 nm). 
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Increased production of reactive oxygen species in neutrophils stimulated by recombinant 
HP-NAP 
 
HP-NAP purified from H. pylori was able to stimulate the production of reactive 
oxygen species (ROS) in neutrophils and monocytes [9,12]. Luminol-dependent 
chemiluminescence (CL) assay was used to determine whether recombinant HP-NAP 
expressed in E. coli also induces ROS production in human neutrophils. To avoid the 
possibility of endotoxin (lipopolysaccharide; LPS) contamination, a syringe filter with 
positively-charged, hydrophilic Mustang E membrane was applied to remove endotoxin from 
purified HP-NAP. As shown in Fig. 3A, a strong CL-response was evoked from neutrophils 
stimulated by PMA, a positive control. HP-NAP without endotoxin removal (unfiltered) 
triggered neutrophils to produce a moderate CL-response in comparison with unstimulated 
control (Fig. 3A). Similarly, HP-NAP with endotoxin removal (filtered) also had the ability to 
promote a CL-response from neutrophils (Fig. 3A). The peak of CL profile appeared around 
13–16 min after the addition of stimuli (Fig. 3A). In order to determine the total responses of 
neutrophils stimulated by HP-NAP, the integral value of CL-response was served as a 
quantitative measure of ROS production. As shown in Fig. 3B, the integral value of 
CL-response of neutrophils stimulated by HP-NAP without endotoxin removal (unfiltered) 
was higher than that of control. HP-NAP with endotoxin removal (filtered) also increased the 
CL-response of neutrophils in comparison with unstimulated control (Fig. 3B). The result 
indicates that recombinant HP-NAP expressed in E. coli induces ROS production in 
neutrophils similar to HP-NAP isolated from H. pylori. 
 
 
Increased release of myeloperoxidase from neutrophils stimulated by HP-NAP 
 
We next investigated whether HP-NAP could induce MPO release from human 
neutrophils using TMB assay. Both HP-NAP without endotoxin removal (unfiltered) and 
HP-NAP with endotoxin removal (filtered) induced significant increases in MPO release 
from neutrophils (Fig. 4A). However, there was no significant difference of MPO activity in 
the extracellular media from neutrophils stimulated by HP-NAP without (unfiltered) and with 
(filtered) endotoxin removal (Fig. 4A). The result indicates that HP-NAP can promote MPO 
release from human neutrophils, which is independent of endotoxin. Although most 
endotoxin was removed from purified HP-NAP, residual endotoxin might stimulate 
neutrophils to release MPO. In order to rule out that endotoxin can activate neutrophils 
directly, LPS was used to examine its effect on MPO release from human neutrophils. As 
shown in Fig. 4B, the release of MPO from neutrophils stimulated by LPS was similar to that 
from untreated control. Thus, endotoxin cannot stimulate neutrophils to release MPO directly 
in vitro. Taken together, recombinant HP-NAP expressed in E. coli can induce degranulation 
of neutrophils with the release of MPO. 
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Fig. 3. Production of ROS from human neutrophils stimulated by HP-NAP. (A) The pattern of 
luminol-dependent chemiluminescence responses of neutrophils stimulated by HP-NAP. Human neutrophils 
(1 × 105 cells) were treated with 1 μM HP-NAP without endotoxin removal (unfiltered) (■), 1 μM HP-NAP 
with endotoxin removal (filtered) (□), 0.08 μM PMA (●) as a positive stimulus, and D-PBS as a negative 
control (○) at 37 °C. The content of ROS generated from neutrophils was measured continuously by using a 
luminol-dependent chemiluminescence (CL) assay as described in Materials and methods. The inset shows 
CL-responses of neutrophils treated with 1 μM HP-NAP and D-PBS. The result was represented as the 
profile of one experiment in triplicate. (B) The integral value of luminol-dependent chemiluminescence 
responses of neutrophils stimulated by HP-NAP. The integral CL signals were used to compare the responses 
of neutrophils treated with 1 μM HP-NAP without endotoxin removal (unfiltered), 1 μM HP-NAP with 
endotoxin removal (filtered), and D-PBS as a negative control. The values shown here are the fold changes 
for treated cells relative to control, which was set to 1. Data were represented as the mean ± S.D. of one 
experiment in triplicate (★, p < 0.05 vs. control). Similar results were obtained in two independent 
experiments. 
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Fig. 4. Effects of HP-NAP and LPS on MPO release from human neutrophils. (A) The release of MPO from 
neutrophils stimulated by HP-NAP. Human neutrophils (1.5 × 105 cells) were exposed to 1 μM HP-NAP 
without endotoxin removal (unfiltered), 1 μM HP-NAP with endotoxin removal (filtered), 0.08 μM PMA as a 
positive stimulus, and D-PBS as a negative control at 37 °C for 30 min. The release of MPO was determined 
by TMB assay as described in Materials and methods. Data were represented as means ± SD of eight 
independent experiments in triplicate (★, p < 0.05 vs. control; n.s., not significant). (B) The release of MPO 
from neutrophils stimulated by LPS. Human neutrophils (1.5 × 105 cells) were exposed to 1 μg/mL LPS and 
D-PBS as a negative control at 37 °C for 30 min. The release of MPO was determined as described in (A). 
Data were represented as means ± SD of six independent experiments in triplicate (n.s., not significant). 
 
 
Discussion 
 
The present study shows that recombinant HP-NAP induces the release of 
myeloperoxidase (MPO) from human neutrophils in addition to stimulating the production of 
reactive oxygen species (ROS). These results indicate that HP-NAP not only involves 
respiratory burst but also results in neutrophil degranulation. The increased amount of MPO 
released from HP-NAP-stimulated neutrophils might contribute to the increased amount of 
MPO found in the gastric mucosa in H. pylori-infected patients. In this study, HP-NAP is 
identified for the first time as a bacterial factor of H. pylori to induce MPO release from 
human neutrophils. 
 
For investigating the effect of HP-NAP on immune cells, endotoxin contamination in 
purified HP-NAP expressed in E. coli should not be neglected. One group has utilized 
polymixin B-coated magnetic beads to remove LPS from purified His-tagged HP-NAP 
expressed in E. coli[21]. However, the efficiency of endotoxin removal was not indicated. We 
have applied a syringe filter with positively-charged, hydrophilic Mustang E membrane to 
remove endotoxin from purified HP-NAP. The recovery of HP-NAP varied from 80% to 
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98.4%, whereas the filtration resulted in more than 97.6% of the amount of endotoxin 
removal from HP-NAP. The residual amount of endotoxin present in purified HP-NAP 
ranged from 0.4 to 14 EU/mg protein. The high efficiency of endotoxin removal and good 
recovery of HP-NAP indicate that this filtration step is a simple and efficient way to remove 
endotoxin from recombinant HP-NAP. 
 
We have removed endotoxin form HP-NAP prior to evaluating its effect on ROS 
production and MPO release from neutrophils. However, one might argue that residual 
endotoxin present in purified HP-NAP may stimulate neutrophils. Previous evidence showed 
that direct LPS stimulation had no significant effect on chemiluminescence generation in 
neutrophils [22]. In addition, plasma factors was required for LPS-inducd ROS production in 
neutrophils [23,24]. Thus, residual endotoxin present in purified HP-NAP could not affect 
ROS production in neutrophils. In terms of MPO release, it has been reported that LPS alone 
induced small but not significant increments in MPO release from neutrophils [25]. Also, 
endotoxin resulted in little or no MPO release from neutrophils in the absence of plasma [26]. 
Our finding that no significant difference in MPO release from human neutrophils stimulated 
by HP-NAP with and without endotoxin removal (Fig. 4A) supports the idea that residual 
endotoxin will neither induce nor prime neutrophils to release MPO. 
 
In summary, HP-NAP can promote human neutrophils to release MPO. MPO generally 
serves as a maker of neutrophil activation and has been considered as an important 
pathophysiological factor in oxidative stress. Future studies are needed to define the basis of 
HP-NAP-induced MPO release from neutrophils in H. pylori-associated gastritis. 
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